Bibliografías temáticas / Inhibiteurs de JAK/STAT / Libros

Libros sobre el tema "Inhibiteurs de JAK/STAT"

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Inhibiteurs de JAK/STAT.
Autor: Grafiati
Publicado: 22 de junio de 2024

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 26 mejores mejores libros para su investigación sobre el tema "Inhibiteurs de JAK/STAT".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore libros sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Nicholson, Sandra E. y Nicos A. Nicola, eds. JAK-STAT Signalling. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-242-1.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Anastasis, Stephanou, ed. JAK-STAT pathway in disease. Austin, Tex: Landes Bioscience, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Decker, Thomas y Mathias Müller, eds. Jak-Stat Signaling : From Basics to Disease. Vienna: Springer Vienna, 2012. http://dx.doi.org/10.1007/978-3-7091-0891-8.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Wilks, Andrew F. y Ailsa G. Harpur. Intracellular Signal Transduction: The JAK-STAT Pathway. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-662-22050-4.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Wilks, Andrew F. Intracellular signal transduction: The JAK-STAT pathway. New York: Springer, 1996.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. CRC Press, 2020.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Stephanou, Anastasis y Bell Richard H. Jr. JAK-STAT Pathway in Disease. Taylor & Francis Group, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

H, Bell Jr Richard. JAK-STAT Pathway in Disease. Taylor & Francis Group, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Nicola, Nicos A. y Sandra E. Nicholson. JAK-STAT Signalling: Methods and Protocols. Humana Press, 2016.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Decker, Thomas y Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer, 2012.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Harpur, Ailsa G. y Andrew F. Wilks. Intracellular Signal Transduction: The JAK-STAT Pathway. Springer, 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Decker, Thomas y Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer London, Limited, 2012.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

Decker, Thomas y Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer, 2012.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

Decker, Thomas y Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer Wien, 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

Wilks, Andrew F. Intracellular Signal Transduction: The Jak-Stat Pathway. Springer, 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

The Jak-Stat pathway in hematopoiesis and disease. Georgetown, Tex: Landes Bioscience/Eurekah.com, 2002.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

Harpur, Ailsa G. y Andrew F. Wilks. The Jak-Stat Pathway (Molecular Biology Intelligence Unit). Springer, 1996.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

Ward, Alister C. The Jak-Stat Pathway in Hematopoiesis and Disease (Molecular Biology Intelligence Unit, 20). Springer, 2002.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Ng, Sze-Ling. The Role of IKKepsilon in JAK/STAT Signaling During the Antiviral Immune Response. 2010.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

Mahdavi, Alborz. Analysis of transient JAK/STAT signaling kinetics predicts control modules of stem cell fate control. 2006.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

Jakstat Signalling Methods And Protocols. Humana Press, 2012.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Resumen
Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling, by targeting multiple RA-associated cytokine pathways, has the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key immune cells. Fostamatinib disodium is an orally available inhibitor of spleen tyrosine kinase (SyK), which is a cytoplasmic tyrosine kinase that is an important mediator of immunoreceptor signalling in mast cells, macrophages, neutrophils, and B cells. Interruption of SyK signalling may interrupt production of tumour necrosis factor (TNF) and metalloproteinase and therefore affect RA disease activity. Tofacitinib has been investigated in multiple phase 2 and phase 3 trials which have investigated its efficacy (clinical, functional, and radiographic) and safety in patients who have failed disease-modifying anti-inflammatory drugs (DMARDs) as monotherapy or in combination with DMARDs, compared to an inhibitor of tumour necrosis factor alpha (TNFα‎) and in patients who have failed TNFα‎ inhibitors. The efficacy of fostamatinib and baricitinib has been investigated in phase 2 trials; both are in large phase 3 clinical programmes. Each of these medications has demonstrated efficacy; their safety profile has been shown to be different from each other and from currently approved biological agents. This chapter discusses what is currently known and understood about their efficacy and safety.
También puede estar interesado en las bibliografías sobre el tema "Inhibiteurs de JAK/STAT" para otros tipos de fuentes:
Artículos de revistas Tesis

Pasar a la bibliografía